# Tezepelumab improved chronic eosinophilic pneumonia in severe asthma patients with liver cirrhosis

## TL;DR

Tezepelumab helped a patient with chronic eosinophilic pneumonia and liver cirrhosis avoid harmful corticosteroids while improving asthma and sinusitis.

## Contribution

Demonstrates tezepelumab's potential as a corticosteroid-sparing treatment for CEP in patients with liver dysfunction.

## Key findings

- Tezepelumab improved asthma and CEP without worsening liver cirrhosis.
- Sinusitis improved after stopping oral corticosteroids.
- Treatment was well-tolerated in a patient with severe comorbidities.

## Abstract

Systemic administration of corticosteroids is used in the treatment of chronic eosinophilic pneumonia (CEP). However, in patients with CEP as well as other comorbidities, the adverse effects of corticosteroids should be minimized as much as possible. A 71-year-old woman was presented with aggravating asthma with CEP and sinusitis, and she had uncompensated liver cirrhosis (LC) with a Child-Pugh score of 7. Initial treatment with a low dose of oral corticosteroids (OCSs) in combination with tezepelumab, an anti-thymic stromal lymphopoietin (TSLP) antibody, resulted in rapid improvement of asthma and CEP without deteriorating LC. Sinusitis also improved after ceasing OCS. This case suggested that tezepelumab may be useful as a treatment option for patients with CEP, especially those with liver dysfunction.